Boston, MA — October 20, 2025 — Receptor.AI, a technology-driven drug discovery company, today announced a collaboration with Oragenics, Inc., a clinical-stage biopharmaceutical company, to accelerate the discovery of potential therapeutic candidates for neurological disorders.

Under the collaboration, Receptor.AI will apply its proprietary AI platform to analyze molecules acquired by Oragenics in late 2023 and generate data-driven hypotheses on receptor binding profiles relevant to neurological disorders such as Alzheimer’s disease, dementia, PTSD, and anxiety. The partnership aims to enhance the efficiency of early-stage discovery by providing structure-based predictions of compound–target interactions to guide focused laboratory validation.

Receptor.AI will leverage its advanced AI platform with the goal of accelerating discovery for Oragenics’s CNS programs. The collaboration will combine an LLM–based target profiling with proteome-wide drug–target interaction (DTI) screening across more than 9,000 human proteins. Receptor.AI anticipates it will then retrain a project-specific DTI model fine-tuned to the unique chemical and biological space of Oragenics’s assets.

It is further anticipated that predicted top-ranked interactions will be further analyzed using Receptor.AI’s proprietary ArtiDock AI docking engine, LLM-based pocket identification, and induced-fit docking workflows to reveal likely binding modes and molecular interactions. Each compound will also undergo extensive profiling across more than 60 ADME-Tox, physicochemical, and drug-likeness parameters, ensuring that the most promising candidates are prioritized for experimental validation.

“Early discovery benefits when AI narrows the option space with transparent, testable outputs,” said Dr. Alan Nafiev, CEO of Receptor.AI. “We will deliver ranked targets and binding-mode hypotheses to help Oragenics focus resources on the most promising avenues—anchoring every decision in subsequent experimental data.”

“By leveraging the technology at Receptor.AI to guide our preclinical work, we believe we can focus resources on the most promising opportunities and potentially accelerate our path to identifying new treatments for a wide range of neuropsychiatric conditions,” said Janet Huffman, CEO of Oragenics.

About Oragenics, Inc.

Oragenics, Inc. is a development-stage biopharmaceutical company pioneering intranasal drug delivery for neurological disorders. Its lead candidate, ONP-002, is a first-in-class neurosteroid delivered through a proprietary intranasal system designed for rapid brain absorption. ONP-002 has shown broad brain biodistribution and the ability to reduce inflammation and oxidative stress—key factors in concussion recovery. With the global concussion treatment market projected to reach $8.9 billion by 2027, ONP-002 represents a novel approach to a major unmet medical need.

About Receptor.AI

Receptor.AI is a next-generation TechBio company transforming drug discovery through AI-native infrastructure and deep modality expertise. With a validated track record across more than 40 discovery programs, the company integrates machine learning, physics-based modeling, and automated decision-making into a unified R&D platform. Receptor.AI drives innovation across small molecules, peptides, and induced proximity therapeutics, partnering with global biopharma and academic institutions to unlock challenging targets and accelerate the path from concept to clinic.

Press & Media Inquiries 

Tetiana Skakun 

Marketing Operations Specialist 

Receptor.AI 

tetiana.skakun@receptor.ai